Szisztémás szklerózis (szkleroderma): vizsgálatok itt: Brazília
6 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Belo Horizonte, Porto Alegre, Rio de Janeiro, Salvador, São Paulo
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peopleA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Where
- Curitiba, Porto Alegre, Recife, Salvador, São Paulo, Valinhos
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00 - 2/3. fázisTaking peopleA Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- Where
- Belo Horizonte, Curitiba, Juiz de Fora, Porto Alegre, Salvador, São Paulo
- Életkor
- 18 év and over
- People
- 300 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Brasília, Cuiabá, Porto Alegre, Rio Grande, São Paulo
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - 4. fázisTaking peopleSafety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
- Where
- São Paulo
- Életkor
- 12 év to 59 év
- People
- 477
- Run by
- University of Sao Paulo General Hospital
See details and how to joinNCT07087912 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Porto Alegre, Salvador, São Paulo
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00